Education
About Us
Working with TipRanks
Follow Us
ME Therapeutics Holdings, Inc. (TSE:METX)
:METX
METX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.75 - C$9.07
Previous CloseN/A
Volume600.00
Average Volume (3M)131.00
Market Cap
N/A
Enterprise ValueC$94.50M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta-0.71
Next Earnings
Mar 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding26,189,493
10 Day Avg. Volume340
30 Day Avg. Volume131
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-375.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
ME Therapeutics Holdings, Inc. News
PremiumCompany Announcements
ME Therapeutics Engages Lucosky Brookman to Explore NASDAQ or NYSE UplistingPremiumCompany Announcements
ME Therapeutics’ mRNA Candidate Shows Promising Anti-Cancer ResultsPremiumCompany Announcements
ME Therapeutics Appoints Karim Lalji as CBOPremiumCompany Announcements
ME Therapeutics Expands Drug Development and FacilitiesPremiumCompany Announcements
ME Therapeutics Begins Testing mRNA Cancer TreatmentsPremiumCompany Announcements
ME Therapeutics Partners for mRNA Cancer TherapiesPremiumCompany Announcements
ME Therapeutics Showcases Innovations at Key EventsPremiumCompany Announcements
ME Therapeutics Celebrates CSE Bell-Ringing Event---
Options Prices
Currently, No data available
---
Ownership Overview
METX FAQ
What was ME Therapeutics Holdings, Inc.’s price range in the past 12 months?
ME Therapeutics Holdings, Inc. lowest stock price was C$0.75 and its highest was C$9.07 in the past 12 months.
What is ME Therapeutics Holdings, Inc.’s market cap?
Currently, no data Available
When is ME Therapeutics Holdings, Inc.’s upcoming earnings report date?
ME Therapeutics Holdings, Inc.’s upcoming earnings report date is Mar 24, 2025 which is in 7 days.
How were ME Therapeutics Holdings, Inc.’s earnings last quarter?
ME Therapeutics Holdings, Inc. released its earnings results on Jan 21, 2025. The company reported -C$0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.012.
Is ME Therapeutics Holdings, Inc. overvalued?
According to Wall Street analysts ME Therapeutics Holdings, Inc.’s price is currently Overvalued.
Does ME Therapeutics Holdings, Inc. pay dividends?
ME Therapeutics Holdings, Inc. does not currently pay dividends.
What is ME Therapeutics Holdings, Inc.’s EPS estimate?
ME Therapeutics Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ME Therapeutics Holdings, Inc. have?
ME Therapeutics Holdings, Inc. has 26,189,493 shares outstanding.
What happened to ME Therapeutics Holdings, Inc.’s price movement after its last earnings report?
ME Therapeutics Holdings, Inc. reported an EPS of -C$0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 25%.
Which hedge fund is a major shareholder of ME Therapeutics Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:METX
---
Company Description
ME Therapeutics Holdings, Inc.
ME Therapeutics is a pre-clinical biopharmaceutical company dedicated to the discovery and development of novel cancer immunotherapies. Using our combined expertise in tumour immunology, T cell biology and myeloid cell development, we are developing biological and small molecule drugs to target novel pathways involved in cancer-induced immune suppression. Our therapies have the potential to work on their own and in combination with other cancer immunotherapies across several cancer types.
---
Technical Analysis
---